Live
10x Genomics BlogLiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - BioSpaceThermo FisherThermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking AlphaMOONS'How Artemis will help the U.S. create a moon base - NBC NewsAgilentAgilent Technologies Inc (A) Shares Fall 5.0% -- What GF Score o - GuruFocusThermo FisherThermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatchFierceBiotechDespite data concerns, Roche’s oral SERD can still be largest product in company history: execFierceBiotechRegeneron ushers in new genetic medicine era with groundbreaking gene therapy approvalThermo FisherThermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company - The Business Journals10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - StockStoryAgilentEarnings snapshot: Agilent Technologies misses FQ1 estimates; gives FQ2 and raises FY26 outlook, above forecast - MSNThermo FisherThermo Fisher Scientific Inc. Q1 2026 Earnings Call Summary - Yahoo Finance10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - TradingView
Endpoints News 18 déc. 2025

Takeda's $4B immunology drug achieves first Phase 3 successes

Takeda's $4B immunology drug achieves first Phase 3 successes

Original
Contenu indisponible. Consultez la source originale.